News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,686 Results
Type
Article (14204)
Company Profile (282)
Press Release (252200)
Section
Business (79508)
Career Advice (153)
Deals (13227)
Drug Delivery (35)
Drug Development (50465)
Employer Resources (31)
FDA (5725)
Job Trends (5127)
News (144426)
Policy (10036)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21634)
ALS (61)
Alzheimer's disease (826)
Antibody-drug conjugate (ADC) (87)
Approvals (5741)
Artificial intelligence (108)
Autoimmune disease (11)
Automation (5)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (19)
Breast cancer (141)
Cancer (1304)
Cardiovascular disease (110)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (307)
Cervical cancer (8)
Clinical research (40910)
Collaboration (497)
Compensation (219)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1362)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1292)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (82)
Earnings (29685)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48155)
Executive appointments (403)
FDA (6347)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (466)
Gene editing (89)
Generative AI (9)
Gene therapy (231)
GLP-1 (357)
Government (1076)
Grass and pollen (2)
Guidances (18)
Healthcare (6591)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (57)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (202)
Leadership (2)
Legal (1387)
Liver cancer (30)
Lung cancer (186)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (48)
Medical device (2590)
Medtech (2591)
Mergers & acquisitions (6253)
Metabolic disorders (364)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1195)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1553)
Now hiring (21)
Obesity (185)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (105)
Partnered (8)
Patents (111)
Patient recruitment (66)
Peanut (35)
People (25508)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14452)
Phase II (19028)
Phase III (12035)
Pipeline (726)
Podcasts (46)
Policy (37)
Postmarket research (853)
Preclinical (6064)
Press Release (30)
Prostate cancer (54)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (274)
Real estate (1414)
Recruiting (12)
Regulatory (8571)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (91)
Series B (60)
Service/supplier (1)
Sickle cell disease (38)
Southern California (1378)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12136)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (151)
Last 7 days (469)
Last 30 days (1652)
Last 365 days (20069)
2025 (4767)
2024 (20554)
2023 (22418)
2022 (26824)
2021 (27809)
2020 (23367)
2019 (16227)
2018 (11741)
2017 (13748)
2016 (11840)
2015 (14353)
2014 (10412)
2013 (7492)
2012 (7533)
2011 (7616)
2010 (7431)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17226)
Australia (2916)
California (3529)
Canada (1051)
China (324)
Colorado (136)
Connecticut (143)
Delaware (88)
Europe (37029)
Florida (414)
Georgia (108)
Idaho (16)
Illinois (211)
India (8)
Indiana (85)
Iowa (1)
Japan (71)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2783)
Michigan (69)
Minnesota (136)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (885)
New Mexico (12)
New York (957)
North Carolina (520)
North Dakota (4)
Northern California (1553)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (675)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1378)
Tennessee (25)
Texas (408)
Utah (48)
Virginia (68)
Washington D.C. (28)
Washington State (321)
Wisconsin (13)
266,686 Results for "cero therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.
June 13, 2024
·
4 min read
Biotech Bay
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company.
February 14, 2024
·
2 min read
Biotech Bay
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes
CERo Therapeutics Holdings, Inc., announces it is presenting preclinical data on its lead product candidate CER-1236 at the Stanford Drug Discovery Symposium, which is being held April 29-30, 2024 in Palo Alto, Calif.
April 30, 2024
·
4 min read
Biotech Bay
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients
CERo Therapeutics Holdings, Inc., today announced the publication in Clinical Cancer Research , a journal of the American Association for Cancer Research, a paper titled “ Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia.”
March 7, 2024
·
4 min read
Deals
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
CERo Therapeutics, Inc. (“CERo”) and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (“PBAX”), a special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement.
June 5, 2023
·
15 min read
Biotech Bay
CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard-of-Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models
CERo Therapeutics, Inc., today announced new preclinical data to be presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrating significant anti-tumor effects of chimeric engulfment receptor (CER) T cells when combined with small molecule therapies in both hematologic and solid tumor models.
May 2, 2022
·
4 min read
Biotech Bay
CERo Therapeutics’ Novel Chimeric Engulfment Receptor T Cells Exhibit Multifunctional Properties and Enhanced Tumor Killing
CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development of novel autologous engineered immune cell therapies, presented the results from preclinical in vitro studies describing the characterization of novel chimeric engulfment receptor T cells.
November 12, 2021
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Repare Therapeutics to Cut Staff Again, This Time by 75%
The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.
February 25, 2025
·
2 min read
·
Angela Gabriel
Press Releases
CRISPR Therapeutics Announces Transition of Chief Operating Officer
March 26, 2025
·
1 min read
1 of 26,669
Next